Description

ARA-290 (Cibinetide) – 20mg

ARA-290, also known as Cibinetide, is an 11-amino acid synthetic peptide derived from the tertiary structure of erythropoietin (EPO). It is engineered to selectively activate the Innate Repair Receptor (IRR), a heteromeric receptor complex composed of the erythropoietin receptor and the beta common receptor (CD131), without stimulating erythropoiesis.

This peptide is developed strictly for laboratory investigation into cytoprotective signaling, inflammatory modulation pathways, and small fiber nerve repair research.

Purity: >99% (HPLC Tested)
Format: Lyophilized White Powder
Molecular Formula: C51H84N16O21
Research Target: Innate Repair Receptor (IRR) & JAK2-Mediated Signaling

Unlike full-length erythropoietin, ARA-290 does not activate hematopoietic pathways responsible for red blood cell production. Instead, it selectively engages tissue-protective signaling cascades associated with anti-inflammatory regulation and cellular stress response mechanisms. This receptor-specific profile makes ARA-290 a focused compound in non-erythropoietic EPO research models.

Research Observed Outcomes

Data from preclinical and translational research programs highlight the following findings in controlled laboratory models:

Anti-Inflammatory Cytokine Regulation:
ARA-290 has been shown to reduce pro-inflammatory cytokine expression including TNF-alpha and IL-1 beta in cellular stress models.

Neuropathic Signaling Research:
Studies indicate improved small fiber nerve density and reduced neuropathic signaling markers in experimental models.

Endothelial Protection:
Laboratory investigations demonstrate enhanced endothelial stability and reduced vascular inflammatory stress markers.

JAK2 Pathway Activation:
Research suggests selective activation of protective JAK2-mediated signaling without stimulation of erythropoiesis.

Ischemic Stress Modulation:
Experimental models show improved tissue resilience following ischemia-reperfusion conditions.

Key Linked Studies & Research References

Innate Repair Receptor Mechanism:
Brines, M., et al. (2008). “Erythropoietin-derived peptide protects against tissue injury.” Proceedings of the National Academy of Sciences.

Neuropathy Research:
Dahan, A., et al. (2013). “ARA-290 improves neuropathic symptoms.” Molecular Medicine.

IRR Signaling Pathways:
Brines, M., & Cerami, A. (2012). “The receptor that tames the innate immune response.” Molecular Medicine.

Endothelial Protection Research:
Zhang, Y., et al. (2015). “Cibinetide modulates inflammatory signaling.” Experimental Neurology.

Storage & Stability Protocols

To preserve peptide structure and functional stability:

Lyophilized Powder:
Store at -20°C for long-term stability. Stable at room temperature for short-term transit.

Reconstituted Stability (Bacteriostatic Water):
When reconstituted under sterile laboratory conditions, solution stability is typically maintained for 4–6 weeks under refrigeration (2°C – 8°C).

Reconstituted Stability (Sterile Water):
Stability is significantly shorter, typically 7–12 days due to absence of antimicrobial preservatives.

Handling:
Avoid repeated freeze-thaw cycles. Protect from excessive heat, light, and agitation during reconstitution.

⚠️ STRICT COMPLIANCE NOTICE: FOR LABORATORY RESEARCH ONLY
This product is a chemical research peptide intended strictly for in vitro or laboratory experimentation. Any form of ingestion, injection, or topical application to humans or animals is STRICTLY PROHIBITED. This product is not a drug, food, or cosmetic and has not been approved by the FDA for any medical application. Handling must be performed by qualified professionals in controlled laboratory environments.